In the new crown drug research and development, China’s new drug research and development strength has been strengthened, and the strength is becoming more and more obvious. More than 50 new crown drugs have been approved for clinical trials. China’s first three anti COVID-19 drugs have been approved for sale. After two years of research and development, China’s original new crown drugs are or will soon take part in the battle to end the new crown pandemic.

◎ our reporter Zhang Jiaxing

The latest statistics of the State Drug Administration show that by the end of February 2022, more than 50 new crown drugs have been approved to enter the clinical trial stage, one neutralizing antibody new crown drug has been approved to market, and the new anti epidemic “tripartite” traditional Chinese medicine has been approved to market

After two years of research and development, China’s top scientific research team has been tackling all kinds of different aspects, such as blocking virus replication, blocking virus invasion, adjusting immune system, etc., and blocking COVID-19 attacks. China’s original new crown drugs are or are about to take part in the battle to end the new crown pandemic.

Explain the curative effect of traditional Chinese medicine with scientific methods

In March 2, 2021, covid-19, Qingfei detoxification granule, Huashi Baidu granule and Xuan lung toxin particles, which played an important role in the fight against the new crown pneumonia, were approved for listing on the three sides.

“These three prescriptions have been explored in practice and evaluated in use. They are indeed effective in clinic.” Zhang Boli, deputy to the National People’s Congress, academician of the Chinese Academy of engineering and honorary president of Tianjin University of traditional Chinese medicine, said that traditional Chinese medicine stresses “the great epidemic produces good medicine”. On the basis of clinical practice, it optimizes and combines classic famous prescriptions, and adds experimental effective traditional Chinese medicine components, so as to develop new traditional Chinese medicine that can significantly improve symptoms, reduce weight conversion rate, promote nucleic acid negative conversion and reduce sequelae, It is also a way of rapid screening and evaluation of new drugs.

Taking Xuanfei Baidu granule as an example, it is composed of five classic famous prescriptions, such as Maxing Shigan Decoction and Qianjin Weigan decoction. At the same time, we added the traditional Chinese medicine ingredients selected from the experiment and symptomatic treatment of COVID-19. Zhang Boli explained that, for example, the component of Polygonum cuspidatum has a significant effect on inhibiting coronavirus replication, while the inflammatory effect of a component of Verbena on small airways is very clear, and its addition can enhance the curative effect.

Zhang Boli covid-19 has carried out a network pharmacology study of Xuan Fei Du Fang in order to further evaluate the efficacy of Chinese medicine by modern means. The effective pathway of compounds and targets has been combed, and functional relationships and mechanism prediction have been analyzed. The mechanism of innovative Chinese medicine for treating new crown pneumonia has been explained.

“Through experiments, we found that Xuanfei Baidu recipe can inhibit the replication of coronavirus to a certain extent, but the more important thing is to regulate the immune function of the body so that the immune response caused by virus invasion will not be over activated and cause inflammatory mediator storm.” How to effectively answer a series of questions such as how to improve the efficacy of traditional Chinese medicine through a series of tests, such as the mechanism of traditional Chinese medicine and the efficacy of traditional Chinese medicine.

“After analyzing the covid-19, the target and the mechanism of action, we found that the target and mechanism of” three drugs and three parties “in different periods of new crown pneumonia were different from light, ordinary and heavy. It also explained why Chinese medicine could fight COVID-19 in all stages. Zhang Boli said that clarifying and clarifying the mechanism of traditional Chinese medicine with modern evaluation means will be more conducive to transmitting the curative effect of traditional Chinese medicine through the international discourse system and contributing to global epidemic prevention and control.

Starting from clinical needs

The research, development and creation of new drugs are closely related to people’s life and health, and face the needs of people’s life and health. “New drug research and development should face clinical problems and identify the development endpoint in order to grasp the innovation direction of new drug creation.” Academician Wang Chen, member of the National Committee of the Chinese people’s Political Consultative Conference, vice president of the Chinese Academy of engineering and President of the Chinese Academy of Medical Sciences, said that the path of new drug research and development in the world is generally based on clinical needs, laboratories (through mechanism research) find targets, and companies follow up (transform) research. However, the source of new drug research in China is to find targets from foreign literature According to foreign original research drugs, carry out secondary innovation and other problems.

“China is rich in clinical research resources and will encounter many problems in clinic. These problems are the source of pharmaceutical innovation.” Wang Chen explained, for example, that a small molecule reagent drug needed for respiratory diagnosis has not been developed in China and has been replaced by industrial preparations. This problem was not solved until clinicians cooperated with pharmaceutical experts in research and development.

A large number of clinical needs are the “question bank” of pharmaceutical innovation and development. There are still two problems in how to make good use of this “question bank”.

On the one hand, clinicians lack the atmosphere to invest in scientific research. Wang Chen believes that doctors’ involvement in clinical research and responsibility for knowledge creation will promote the original innovation of medicine and pharmacy in China. On the other hand, China’s clinical resources have not been fully utilized. Wang Chen said that for example, in the global registered clinical studies, the number of registered studies in China only accounts for about 3%. To adhere to the “four aspects” of pharmaceutical innovation and R & D, we must fully stimulate the willingness of clinicians to explore clinical needs and integrate more deeply into the whole ecological chain of pharmaceutical R & D.

Meet the revolutionary changes in the pharmaceutical industry

“Life science is no longer just a matter for biologists, including the integrated development of physics, chemistry, mathematics, information science, material science, engineering science and other disciplines, so as to jointly promote the development of life science.” Chen Kaixian, academician of the Chinese Academy of Sciences, said.

Meet the revolutionary changes in the pharmaceutical industry and gradually enhance the entrepreneurial ability of Chinese enterprises; The national science and technology plan has successively set up major special projects and key R & D plans related to new drug R & D in the layout. According to the latest data released by McKinsey in 2020, China’s new drug R & D accounts for 13.9% of the world, ranking the second echelon.

In the new crown drug research and development, China’s new drug research and development strength has been strengthened, and the strength is becoming more and more obvious. In December 8, 2021, China’s first anti COVID-19 drug, the new crown neutralizing antibody, the combination of the monoclonal antibody and the romicwell monoclonal antibody, was approved. The combination drug was jointly developed by Tsinghua University, Shenzhen Third People’s Hospital and tengshengbo pharmaceutical.

Zhang Linqi, the leader of the R & D team and professor of Tsinghua University School of medicine, previously said that each laboratory has its own talents and will choose partners to join the work of new drug creation based on the technical platform and accumulation previously owned by each laboratory.

Well prepared, it is the creation and research of new crown drugs in China